Right heart function in PAH improves with investigational oral therapy CS1
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
Marisa Wexler is a senior science writer for Pulmonary Hypertension News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.| Pulmonary Hypertension News
